Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A8ZD
|
|||
| Former ID |
DIB003282
|
|||
| Drug Name |
SR-33805
|
|||
| Synonyms |
SR 33805; 121345-64-0; AC1L2VL6; SCHEMBL7268066; CHEMBL287679; DTXSID40153241; 3,4-Dimethoxy-N-methyl-N(3-(4-((1-methyl-2-(1-methylethyl)-1H-indol-3-yl)sulfonyl)phenoxy)propyl)benzeneethanamine; N-[3-[4-[(1-Methyl-2-isopropyl-1H-indol-3-yl)sulfonyl]phenoxy]propyl]-N-methyl-3,4-dimethoxyphenethylamine; N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[4-(1-methyl-2-propan-2-ylindol-3-yl)sulfonylphenoxy]propan-1-amine; Benzeneethanamine, 3,4-dimethoxy-N-methyl-N(3-(4-((1-methyl-2-(1-methylethyl)-1H-indol-3-yl)sulfonyl)phen
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Angina pectoris [ICD-11: BA40; ICD-9: 413] | Discontinued in Phase 1 | [1] | |
| Company |
Sanofi
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H40N2O5S
|
|||
| Canonical SMILES |
CC(C)C1=C(N(C2=CC=CC=C21)C)S(=O)(=O)C3=CC=C(C=C3)OCCCN(C)CCC4=CC(=C(C=C4)OC)OC
|
|||
| InChI |
1S/C32H40N2O5S/c1-23(2)31-27-10-7-8-11-28(27)34(4)32(31)40(35,36)26-15-13-25(14-16-26)39-21-9-19-33(3)20-18-24-12-17-29(37-5)30(22-24)38-6/h7-8,10-17,22-23H,9,18-21H2,1-6H3
|
|||
| InChIKey |
GCVFQRRBTCHIPK-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcium channel unspecific (CaC) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002436) | |||
| REF 2 | Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1348-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.